An article posted Dec. 5 by Vocative.com's Elizabeth Kulse started a minor ripple effect in the abortion lobby blogosphere, with Slate.com and The Daily Mail, among others, following suit in the following days.
The story? An effort launched more than two years ago by Dr. George Delgado, M.D., F.A.A.F.P. to reverse the effects of Mifepristone, the first in a two-pill regimen known as RU-486, or simply, "the abortion pill."
The article(s) call into question both the demand and the methodology behind the procedure, partially on the purported testimonial strength of Dr. Daniel Grossman, an OB-GYN who is professor at UC San Francisco's pro-abortion Bixby Center for Global Reproductive Health.
Quoted in the Vocativ.com article, Dr. Grossman, a member of the American College of Obstetricians and Gynecologists, argues that the number of women accessing the service is not enough to warrant the service itself. Dr. Grossman is quoted as claiming that immediate regret following the initial dose of RU-486 is “exceedingly rare.”
Standing in opposition to Dr. Grossman's statements are the 77 women and children who stand as actual "outcomes"—actual lives that would not have been if not for the service offered by AbortionPillReversal.com and its network of 226 pro-life OB-GYNs who are prepared to provide an early dose of supplemental progesterone to block the effects of Mifepristone—the first of two pills administered in the RU-486 regimen.
“We are grateful for Dr. Delgado's work,” Heartbeat International President Peggy Hartshorn, Ph.D., said. “It is a shame to see his good work besmirched by agenda-driven writers, determined to grow the business of abortion.
“The tragic thing is that real women who have either been helped by this treatment or wish that they had been, are being silenced and gagged in the process,” Hartshorn said. “Pregnancy help organizations like Dr. Delgado’s offer each and every woman the true compassion, support, and choice she deserves.”
The articles—released over two years after Heartbeat International reported the site’s launch and first distributed a webinar on the procedure through Heartbeat Academy—cite the small sample size of women included in an initial peer-reviewed 2012 report published by Dr. Delgado.
Dr. Delgado’s team is currently reviewing its cases from the time of the initial report—which included 28 contacts and four births following ingestion of Mifepristone from May to December, 2012.
Neither Dr. Delgado nor his team were ever contacted by reporters linked to the recent articles.
